Evidence map›Paper›PMID 30013391›Full record

ReviewCancer management and research2018

Recent advances in antiemetics: new formulations of 5HT

James Gilmore, Steven D'Amato, Niesha Griffith, Lee Schwartzberg

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Intergenerational comparison of 5-HTSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James GilmoreClinical Services, Georgia Cancer Specialists, Atlanta, GA, USA, james.gilmore@gacancer.com.
Steven D'AmatoDepartment of Clinical Pharmacy Services, New England Cancer Specialists, Scarborough, ME, USA.
Niesha GriffithWest Virginia University Medicine, Morgantown, WV, USA.
Lee SchwartzbergWest Cancer Center.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT SUMMARY: CINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24-120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT

conclusionRecent updates in antiemetic guidelines and the development of newer antiemet-ics should help mitigate CINV, this dreaded side effect of chemotherapy. GERSC, the most recently approved 5HT

Indexed as

chemotherapy-induced nausea and vomitinggranisetrongranisetron extended-release injectiongranisetron extended-release subcutaneousserotonin-receptor antagonist

Identifiers

PMID30013391
PMCPMC6037149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.